A boceprevir failure in a patient infected with HCV genotype 1g: Importance and limitations of virus genotyping prior to HCV protease-inhibitor-based therapy

Antiviral Therapy

Volumn 18, Issue 4, 2013, Pages 645-648

  Cento, Valeria ^a   Landonio, Simona ^b   De Luca, Francesca ^a   Di Maio, Velia C ^a   Micheli, Valeria ^b   Mirabelli, Carmen ^a   Niero, Fosca ^b   Magni, Carlo ^b   Rizzardini, Giuliano ^b   Perno, Carlo F ^a   Ceccherini Silberstein, Francesca ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; LEUCINE; NONSTRUCTURAL PROTEIN 3; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; PHENYLALANINE; PROLINE; SERINE; THREONINE; VIRUS RNA;

ADULT; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; BINDING SITE; CASE REPORT; DISEASE CLASSIFICATION; DRUG RESPONSE; DRUG TREATMENT FAILURE; GENETIC SIMILARITY; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HUMAN; MALE; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

ADULT; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GENOTYPING TECHNIQUES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PHYLOGENY; PROLINE; PROTEASE INHIBITORS; TREATMENT FAILURE; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84880359255     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2529     Document Type: Article

References (22)

1. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54:1433-1444.
2. Chevaliez S. Virological tools to diagnose and monitor hepatitis C virus infection. Clin Microbiol Infect 2011; 17:116-121.
3. Kieffer TL, De MS, Bartels DJ, et al. Hepatitis C viral evolution in genotype 1 treatment-naive and treatmentexperienced patients receiving telaprevir-based therapy in clinical trials. PLoS ONE 2012; 7:e34372.
4. De Meyer S, Dierynck I, Ghys A, et al. Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the realize trial. Hepatology 2012; 56:2106-2115.
5. Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol 2011; 55:192-206.
6. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010; 138:447-462.
7. Soriano V, Vispo E, Poveda E, Labarga P, Barreiro P. Treatment failure with new hepatitis C drugs. Expert Opin Pharmacother 2012; 13:313-323.
8. Cento V, Mirabelli C, Salpini R, et al. HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. PLoS ONE 2012; 7:e39652.
9. Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007; 46:631-639.
10. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360:1827-1838.
11. Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132:1767-1777.
12. Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM. Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. PLoS ONE 2009; 4:e8209.
13. Nakano T, Lau GM, Lau GM, Sugiyama M, Mizokami M. An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region. Liver Int 2012; 32:339-345.
14. Cento V, De Luca F, Di Maio C, et al. Characterization of baseline NS3 protease polymorphisms and drug resistance development in HCV-1-infected patients starting a proteaseinhibitor-containing regimen. Antivir Ther 2012; 17 Suppl 1:A98.
15. Susser S, Welsch C, Wang Y, et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009; 50:1709-1718.
16. Bracho MA, Saludes V, Martro E, Bargallo A, Gonzalez-Candelas F, Ausina V. Complete genome of a European hepatitis C virus subtype 1g isolate: phylogenetic and genetic analyses. Virol J 2008; 5:72.
17. Abdel-Hamid M, El-Daly M, Molnegren V, et al. Genetic diversity in hepatitis C virus in Egypt and possible association with hepatocellular carcinoma. J Gen Virol 2007; 88:1526-1531.
18. Bartels DJ, Zhou Y, Zhang EZ, et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis 2008; 198:800-807.
19. Colson P, Purgus R, Borentain P, Gerolami R. Natural presence of NS3 protease R155K hepatitis C virus variants with decreased sensitivity to protease inhibitors. J Clin Virol 2012; 53:178-180.
20. Fonseca-Coronado S, Escobar-Gutierrez A, Ruiz-Tovar K, et al. Specific detection of naturally occurring hepatitis C virus mutants with resistance to telaprevir and boceprevir (protease inhibitors) among treatment-naive infected individuals. J Clin Microbiol 2012; 50:281-287.
21. Vallet S, Viron F, Henquell C, et al. NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5. Antivir Ther 2011; 16:1093-1102.
22. UCSF. Chimera 1.5.3 software. (Accessed 18 December 2012.) Available from http://www.cgl.ucsf.edu/index.html